135 related articles for article (PubMed ID: 33155140)
1. Histone Lysine-to-Methionine Mutation as Anticancer Drug Target.
Yang J; Qiu Q; Chen L
Adv Exp Med Biol; 2021; 1283():85-96. PubMed ID: 33155140
[TBL] [Abstract][Full Text] [Related]
2. Histone H3K27M Mutation in Brain Tumors.
El-Hashash AHK
Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
[TBL] [Abstract][Full Text] [Related]
3. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Lu C; Jain SU; Hoelper D; Bechet D; Molden RC; Ran L; Murphy D; Venneti S; Hameed M; Pawel BR; Wunder JS; Dickson BC; Lundgren SM; Jani KS; De Jay N; Papillon-Cavanagh S; Andrulis IL; Sawyer SL; Grynspan D; Turcotte RE; Nadaf J; Fahiminiyah S; Muir TW; Majewski J; Thompson CB; Chi P; Garcia BA; Allis CD; Jabado N; Lewis PW
Science; 2016 May; 352(6287):844-9. PubMed ID: 27174990
[TBL] [Abstract][Full Text] [Related]
4. Histone H3 Mutations in Cancer.
Wan YCE; Liu J; Chan KM
Curr Pharmacol Rep; 2018; 4(4):292-300. PubMed ID: 30101054
[TBL] [Abstract][Full Text] [Related]
5. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
7. S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3.
Jayaram H; Hoelper D; Jain SU; Cantone N; Lundgren SM; Poy F; Allis CD; Cummings R; Bellon S; Lewis PW
Proc Natl Acad Sci U S A; 2016 May; 113(22):6182-7. PubMed ID: 27185940
[TBL] [Abstract][Full Text] [Related]
8. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
9. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas.
Fang D; Gan H; Lee JH; Han J; Wang Z; Riester SM; Jin L; Chen J; Zhou H; Wang J; Zhang H; Yang N; Bradley EW; Ho TH; Rubin BP; Bridge JA; Thibodeau SN; Ordog T; Chen Y; van Wijnen AJ; Oliveira AM; Xu RM; Westendorf JJ; Zhang Z
Science; 2016 Jun; 352(6291):1344-8. PubMed ID: 27229140
[TBL] [Abstract][Full Text] [Related]
10. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling.
Herz HM; Morgan M; Gao X; Jackson J; Rickels R; Swanson SK; Florens L; Washburn MP; Eissenberg JC; Shilatifard A
Science; 2014 Aug; 345(6200):1065-70. PubMed ID: 25170156
[TBL] [Abstract][Full Text] [Related]
11. Histone Lysine-to-Methionine Mutations Reduce Histone Methylation and Cause Developmental Pleiotropy.
Sanders D; Qian S; Fieweger R; Lu L; Dowell JA; Denu JM; Zhong X
Plant Physiol; 2017 Apr; 173(4):2243-2252. PubMed ID: 28202597
[TBL] [Abstract][Full Text] [Related]
12. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
13. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
Zhang X; Zhang Z
Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
[TBL] [Abstract][Full Text] [Related]
14. H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation.
Harutyunyan AS; Chen H; Lu T; Horth C; Nikbakht H; Krug B; Russo C; Bareke E; Marchione DM; Coradin M; Garcia BA; Jabado N; Majewski J
Cell Rep; 2020 Nov; 33(7):108390. PubMed ID: 33207202
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
16. Probe the function of histone lysine 36 methylation using histone H3 lysine 36 to methionine mutant transgene in mammalian cells.
Fang D; Gan H; Wang H; Zhou H; Zhang Z
Cell Cycle; 2017 Oct; 16(19):1781-1789. PubMed ID: 28129023
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
18. Histone H3K36M mutation and trimethylation patterns in chondroblastoma.
Lu C; Ramirez D; Hwang S; Jungbluth A; Frosina D; Ntiamoah P; Healey J; Zhu G; Chen W; Klein M; Hameed M
Histopathology; 2019 Jan; 74(2):291-299. PubMed ID: 30098026
[TBL] [Abstract][Full Text] [Related]
19. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
20. Histone Mutations and Bone Cancers.
Taylor EL; Westendorf JJ
Adv Exp Med Biol; 2021; 1283():53-62. PubMed ID: 33155137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
